FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022782166> ?p ?o ?g. }

• W2022782166 endingPage "307" @default.
• W2022782166 startingPage "298" @default.
• W2022782166 abstract "Stathmin is the founding member of a family of microtubule-destabilizing proteins that have a critical role in the regulation of mitosis. Stathmin is expressed at high levels in breast cancer and its overexpression is linked to disease progression. Although there is a large body of evidence to support a role for stathmin in breast cancer progression, the validity of stathmin as a viable therapeutic target for breast cancer has not been investigated. Here, we used a bicistronic adenoviral vector that co-expresses green fluorescent protein and a ribozyme that targets stathmin messenger RNA in preclinical breast cancer models with different estrogen receptor (ER) status. We examined the effects of anti-stathmin ribozyme on the malignant phenotype of breast cancer cells in vitro and in xenograft models in vivo both as a single agent and in combination with chemotherapeutic agents. Adenovirus-mediated gene transfer of anti-stathmin ribozyme resulted in a dose-dependent inhibition of proliferation and clonogenicity associated with a G2/M arrest and increase in apoptosis in both ER-positive and ER-negative breast cancer cell lines. This inhibition was markedly enhanced when stathmin-inhibited breast cancer cells were exposed to low concentrations of taxol, which resulted in virtually complete loss of the malignant phenotype. Interestingly, breast cancer xenografts treated with low doses of anti-stathmin therapy and taxol showed regression in a majority of tumors, while some tumors stopped growing completely. In contrast, combination of anti-stathmin ribozyme and adriamycin resulted in only a modest inhibition of growth in vitro and in breast cancer xenografts in vivo. Although inhibition of tumor growth was observed in both the combination treatment groups compared with groups treated with single agent alone, combination of anti-stathmin therapy and taxol had a more profound inhibition of tumorigenicity, as both agents target the microtubule pathway. Clinically, these findings are highly relevant because taxol is one of the most active chemotherapeutic agents in breast cancer. These studies provide the proof-of-principle that stathmin provides an attractive molecular target, which could serve as a primary focus of novel approaches to breast cancer." @default.
• W2022782166 created "2016-06-24" @default.
• W2022782166 creator A5006791478 @default.
• W2022782166 creator A5036443120 @default.
• W2022782166 creator A5047580135 @default.
• W2022782166 creator A5055379696 @default.
• W2022782166 date "2013-04-26" @default.
• W2022782166 modified "2023-10-06" @default.
• W2022782166 title "Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer" @default.
• W2022782166 cites W1510189975 @default.
• W2022782166 cites W1523498832 @default.
• W2022782166 cites W1533239574 @default.
• W2022782166 cites W1558893254 @default.
• W2022782166 cites W1565350682 @default.
• W2022782166 cites W169449544 @default.
• W2022782166 cites W1978912122 @default.
• W2022782166 cites W1981081121 @default.
• W2022782166 cites W2003878410 @default.
• W2022782166 cites W2006815328 @default.
• W2022782166 cites W2009785870 @default.
• W2022782166 cites W2017513981 @default.
• W2022782166 cites W2023887187 @default.
• W2022782166 cites W2029128037 @default.
• W2022782166 cites W2039074795 @default.
• W2022782166 cites W2043468746 @default.
• W2022782166 cites W2052247684 @default.
• W2022782166 cites W2067275681 @default.
• W2022782166 cites W2076070642 @default.
• W2022782166 cites W2087842578 @default.
• W2022782166 cites W2094324653 @default.
• W2022782166 cites W2107661846 @default.
• W2022782166 cites W2113385069 @default.
• W2022782166 cites W2128613144 @default.
• W2022782166 cites W2145792449 @default.
• W2022782166 cites W2148163876 @default.
• W2022782166 cites W2170784945 @default.
• W2022782166 cites W2319767540 @default.
• W2022782166 cites W2407026676 @default.
• W2022782166 cites W4232822952 @default.
• W2022782166 doi "https://doi.org/10.1038/cgt.2013.21" @default.
• W2022782166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23618950" @default.
• W2022782166 hasPublicationYear "2013" @default.
• W2022782166 type Work @default.
• W2022782166 sameAs 2022782166 @default.
• W2022782166 citedByCount "29" @default.
• W2022782166 countsByYear W20227821662014 @default.
• W2022782166 countsByYear W20227821662015 @default.
• W2022782166 countsByYear W20227821662016 @default.
• W2022782166 countsByYear W20227821662017 @default.
• W2022782166 countsByYear W20227821662018 @default.
• W2022782166 countsByYear W20227821662019 @default.
• W2022782166 countsByYear W20227821662020 @default.
• W2022782166 countsByYear W20227821662021 @default.
• W2022782166 countsByYear W20227821662022 @default.
• W2022782166 crossrefType "journal-article" @default.
• W2022782166 hasAuthorship W2022782166A5006791478 @default.
• W2022782166 hasAuthorship W2022782166A5036443120 @default.
• W2022782166 hasAuthorship W2022782166A5047580135 @default.
• W2022782166 hasAuthorship W2022782166A5055379696 @default.
• W2022782166 hasBestOaLocation W20227821661 @default.
• W2022782166 hasConcept C104317684 @default.
• W2022782166 hasConcept C121608353 @default.
• W2022782166 hasConcept C150903083 @default.
• W2022782166 hasConcept C20418707 @default.
• W2022782166 hasConcept C207001950 @default.
• W2022782166 hasConcept C2776187077 @default.
• W2022782166 hasConcept C2778654611 @default.
• W2022782166 hasConcept C502942594 @default.
• W2022782166 hasConcept C530470458 @default.
• W2022782166 hasConcept C54355233 @default.
• W2022782166 hasConcept C55493867 @default.
• W2022782166 hasConcept C67705224 @default.
• W2022782166 hasConcept C76346623 @default.
• W2022782166 hasConcept C86803240 @default.
• W2022782166 hasConcept C95444343 @default.
• W2022782166 hasConcept C96232424 @default.
• W2022782166 hasConceptScore W2022782166C104317684 @default.
• W2022782166 hasConceptScore W2022782166C121608353 @default.
• W2022782166 hasConceptScore W2022782166C150903083 @default.
• W2022782166 hasConceptScore W2022782166C20418707 @default.
• W2022782166 hasConceptScore W2022782166C207001950 @default.
• W2022782166 hasConceptScore W2022782166C2776187077 @default.
• W2022782166 hasConceptScore W2022782166C2778654611 @default.
• W2022782166 hasConceptScore W2022782166C502942594 @default.
• W2022782166 hasConceptScore W2022782166C530470458 @default.
• W2022782166 hasConceptScore W2022782166C54355233 @default.
• W2022782166 hasConceptScore W2022782166C55493867 @default.
• W2022782166 hasConceptScore W2022782166C67705224 @default.
• W2022782166 hasConceptScore W2022782166C76346623 @default.
• W2022782166 hasConceptScore W2022782166C86803240 @default.
• W2022782166 hasConceptScore W2022782166C95444343 @default.
• W2022782166 hasConceptScore W2022782166C96232424 @default.
• W2022782166 hasIssue "5" @default.
• W2022782166 hasLocation W20227821661 @default.
• W2022782166 hasLocation W20227821662 @default.
• W2022782166 hasOpenAccess W2022782166 @default.
• W2022782166 hasPrimaryLocation W20227821661 @default.
• W2022782166 hasRelatedWork W2022782166 @default.

• next